C

Cadrenal Therapeutics
D

CVKD

13.590
USD
-0.49
(-3.45%)
مغلق
حجم التداول
563
الربح لكل سهم
-6
العائد الربحي
-
P/E
-2
حجم السوق
27,816,746
الأخبار المقالات

العنوان: Cadrenal Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.